ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

 

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

MHRA Drug Safety Update April 2023 DSU.pdf

MHRA Drug Safety Update April 2023 DSU.pdf
Summary: Isotretinoin (Roaccutaneâ–¼): new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality . Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions
File Size: 345KB
Type: Files / Images
Created: 26 April 2023
Last Modified: 25 May 2023